Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine
Hørsholm, Denmark, March 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The clinical study is now starting with the enrolment of up to 42 study participants to investigate safety and secondary efficacy parameters. First human dosing is planned for March 12, 2021. The CTA approval is